4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
IPO Year:
Exchange: NASDAQ
Website: https://www.4dpharmaplc.com
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq Staff (the "Staff") has determined that 4D pharma's securities will be delisted from The Nasdaq Stock Market. Accordingly, trading of 4D pharma's LBPS will be suspended at the opening of business on July 7, 2022, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove 4D pharma's secur
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company's request for an immediate suspension of trading in the Company's ordinary shares on AIM which took effect from 12.30 p.m. (London). On 29 July 2021, the Company announced that it had agreed a senior secured credit facility (the "Facility") for up to US$30m with Oxford Finance LLC ("Oxford"), with an initial tranche of US$12.5 million drawn at closing and further tranches available dependent on the achievement of certain mileston
- Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months - Study sites are open for patient enrolment 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced the presentation of a trial in progress poster from the Phase II clinical trial of MRx0518 in combination with BAVENCIO® (avelumab), a PD-L1 blocking antibody, as a first-line maintenance therapy for patients with unresectable locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, a
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET. A replay webcast of the presentation will be available via the ‘Events' section of the 4D pharma website at www.4dpharmaplc.com for 90 days following the presentation. About 4D pharma 4d pharma is a world leader in the development of Live Biotherapeutics, a novel and em
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the presentation of a late-breaking poster on data from Part A of the Phase I/II trial of MRx-4DP0004 for the treatment of asthma. The poster is being presented at the 2022 American Thoracic Society (ATS) International Conference, May 13-18, 2022 in San Francisco, CA, US. "The clinical results of MRx-4DP0004 treatment to date reinforce 4D pharma's success in using the MicroRx platform to select single strain LBPs and generate clinical candidates with specific immune-modulating therapeutic functio
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022. "2021 was a productive year for 4D pharma. We reported promising signals in the clinic from our lead candidates in immuno-oncology and inflammatory disease, and entered into our second clinical collaboration in oncology, further validating the potential for single strain Live Biotherapeutics to treat systemic disease and the MicroRx platform. Additionally, we completed the merger wit
- Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study - Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment complet
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will participate in a fireside chat at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 9:00 a.m. ET (2:00 p.m. GMT). A webcast of the fireside chat will be available via the ‘Events' section of the 4D pharma website at www.4dpharmaplc.com and will be available to replay for 90 days following the presentation. About 4D pharma 4D pharma is a world leader in
- IND clearance marks the expansion of 4D pharma's clinical-stage pipeline of single strain Live Biotherapeutics into neurology - First US FDA IND clearance for a Live Biotherapeutic for Parkinson's disease 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that the U.S. Food and Drug Administration (FDA) has cleared investigational new drug (IND) applications for two Live Biotherapeutics (LBPs), MRx0005 and MRx0029, for the treatment of Parkinson's disease. The Company expects to initiate a first-in-human Phase I clinical trial in people with P
- Part A of the trial achieved the primary endpoint of safety and tolerability - Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial - Company to host conference call and webcast to discuss results today at 08:00 a.m. ET (1:00 p.m. GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces additional clinical data from Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
6-K - 4D Pharma PLC (0001830162) (Filer)
25-NSE - 4D Pharma PLC (0001830162) (Subject)
6-K - 4D Pharma PLC (0001830162) (Filer)
4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022. "2021 was a productive year for 4D pharma. We reported promising signals in the clinic from our lead candidates in immuno-oncology and inflammatory disease, and entered into our second clinical collaboration in oncology, further validating the potential for single strain Live Biotherapeutics to treat systemic disease and the MicroRx platform. Additionally, we completed the merger wit
- Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study - Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment complet
- Part A of the trial achieved the primary endpoint of safety and tolerability - Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial - Company to host conference call and webcast to discuss results today at 08:00 a.m. ET (1:00 p.m. GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces additional clinical data from Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.
SC 13G/A - 4D Pharma PLC (0001830162) (Subject)
SC 13G - 4D Pharma PLC (0001830162) (Subject)
SC 13G - 4D Pharma PLC (0001830162) (Subject)
SC 13G/A - 4D Pharma PLC (0001830162) (Subject)
SC 13G - 4D Pharma PLC (0001830162) (Subject)
Upgrades According to Vertical Research, the prior rating for PPG Industries Inc (NYSE:PPG) was changed from Hold to Buy. PPG Indus earned $1.37 in the first quarter, compared to $1.88 in the year-ago quarter. The stock has a 52-week-high of $177.32 and a 52-week-low of $107.06. At the end of the last trading period, PPG Indus closed at $121.01. OTR Global upgraded the previous rating for Chipotle Mexican Grill Inc (NYSE:CMG) from Mixed to Positive. In the first quarter, Chipotle Mexican Grill showed an EPS of $5.70, compared to $5.36 from the year-ago quarter. The current stock performance of Chipotle Mexican Grill shows a 52-week-high of $1958.55 and a 52-week-low of $1196.28. Moreover,
Chardan Capital analyst Keay Nakae downgrades 4d pharma (NASDAQ:LBPS) from Buy to Neutral.
Gainers Ocean Bio-Chem, Inc. (NASDAQ:OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. Phoenix Motor Inc. (NASDAQ:PEV) jumped 70.5% to close at $5.83. Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) gained 47.9% to close at $1.73. Exela Technologies, Inc. (NASDAQ:XELA) gained 39.2% to close at $0.1897 after the company announced a new customer win of $136 million in total contract value. U.S. Well Services, Inc. (NASDAQ:USWS) climbed 37.3% to close at $0.9872 after ProFrac Holding announced plans to acquire the company for $1.21 per share in an all-stock deal.
Gainers Omeros (NASDAQ:OMER) shares increased by 23.7% to $2.71 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 1.3 million shares, making up 150.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $169.9 million. Vor Biopharma (NASDAQ:VOR) stock moved upwards by 23.62% to $5.6. The current volume of 96.9K shares is 93.3% of Vor Biopharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $210.5 million. Better Therapeutics (NASDAQ:BTTX) shares increased by 22.75% to $1.83. As of 13:30 EST, this security is trading at a vo
On Wednesday, 329 companies hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Home Depot (NYSE:HD). The smallest company by market cap to hit a new 52-week low was Performance Shipping (NASDAQ:PSHG). Athira Pharma (NASDAQ:ATHA)'s stock made the biggest move downwards, diving 66.66% to reach a new 52-week low. ASA Gold & Precious Metal (NYSE:ASA)'s stock rebounded the most, as it traded up 0.0% after dropping to a new 52-week low. Here are all the stocks that set new 52-week lows on Wednesday: Home Depot (NYSE:HD) stock hit a yearly low of $264.54. The stock was up 0.15% for the day. Walt Disney (
Gainers Ocean Bio-Chem, Inc. (NASDAQ:OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. Revlon, Inc. (NYSE:REV) surged 47% to $8.91 on continued volatility following the company's recent bankruptcy filing. The stock has also been circulated as a short squeeze candidate. JX Luxventure Limited (NASDAQ:LLL) gained 39.2% to $2.0750. JX Luxventure announced a $5 million buyback and also signed a $30 million sales agreement. U.S. Well Services, Inc. (NASDAQ:USWS) rose 35.1% to $0.9711 after ProFrac Holding Corp. (NASDAQ:PFHC) announced plans to acquire the company for $1.21 per share in an all-stock deal. Ex
Gainers Quotient (NASDAQ:QTNT) shares rose 34.6% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $51.6 million. Codex DNA (NASDAQ:DNAY) stock increased by 22.89% to $2.63. The company's market cap stands at $77.3 million. Aclarion (NASDAQ:ACON) stock moved upwards by 21.6% to $0.99. The market value of their outstanding shares is at $7.7 million. Precision BioSciences (NASDAQ:DTIL) shares increased by 10.07% to $1.53. The company's market cap stands at $95.1 million. Catalyst Biosciences (NASDAQ:CBIO) shares increased by 8.14% to $1.46. The market value of their outstanding shares is at $45.9 million. Alzamend Neuro (NASDAQ:ALZN) s
Gainers Convey Health Solutions Holdings, Inc. (NYSE:CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. Valneva SE (NASDAQ:VALN) gained 93.1% to close at $26.48. Pfizer will invest €90.5 million ($95 million) for an 8.1% stake in Valneva, as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15. Revlon, Inc. (NYSE:REV) climbed 62.5% to close at $6.06. Revlon shares jumped 91% on Friday following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. Great Panther Mining Limited (NYSE:GPL) surged 51.8% to close at $0.1518. G Medical Innova
Gainers Convey Health Solutions Holdings, Inc. (NYSE:CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. Valneva SE (NASDAQ:VALN) gained 79.4% to $24.60. Pfizer will invest €90.5 million ($95 million) for an 8.1% stake in Valneva, as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15. BlackSky Technology Inc. (NYSE:BKSY) shares jumped 26.4% to $2.5650. BlackSky won a 5-year joint Artificial Intelligence Center contract for AI data readiness. Phoenix New Media Limited (NYSE:FENG) gained 26.2% to $5.88. Argo Blockchain plc (NASDAQ:ARBK) jumped 23.9% to $4.66. PermRock Royalty Trust (NYSE:PRT) gained 22.3%
During Monday's trading, 1214 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Microsoft (NASDAQ:MSFT). Quoin Pharmaceuticals (NASDAQ:QNRX) was the smallest company by market cap to set a new 52-week low. DexCom (NASDAQ:DXCM)'s stock fell the most, as it traded down 76.5% to reach a new 52-week low. La Jolla Pharmaceutical (NASDAQ:LJPC)'s stock made the biggest bounce back, actually moving up 0.0% shortly after hitting a new 52-week low. On Monday, the following stocks broke to new 52-week lows: Bank of America (NYSE:BAC) stock hit a yearly low of $31.99. The stock was down 3.01% for th